EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 299 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR From Scan to Scan: The Challenges of Living with Metastatic Cancer October 15, 2021 Routes to a healthier shopping journey – how your supermarket environment... April 19, 2023 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 9, 2020 Load more HOT NEWS Into the archives: the story of HPV and cervical cancer What to Know About Treatment Options Before and After Surgery for... No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to...
